What one share of Liminatus Pharma holds
Liminatus is a pre-clinical stage, single-asset biopharmaceutical company. Liminatus is developing novel cancer therapies that exploit the body’s immune system. The Company’s clinical candidate is a humanized anti CD47 monoclonal antibody.
Liminatus Pharma’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.36 |
|---|---|
| Cash and investments | $0.05 |
| Book value | $0.01 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2024 | — | −$0.20 | — | — | — | −$1.11 |
| 2025 | — | −$0.43 | $0.00 | −$0.42 | — | −$0.36 |
Common questions about Liminatus Pharma
How much does one share of Liminatus Pharma earn?
Over the last 12 months, Liminatus Pharma lost $0.36 for each share.
Does Liminatus Pharma pay a dividend?
Liminatus Pharma didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Liminatus Pharma’s book value per share?
Liminatus Pharma’s book value is $0.01 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Liminatus Pharma have?
Each share of Liminatus Pharma has $0.05 of cash and investments, as of June 30, 2026.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.